Expert Review of Molecular Diagnostics最新文献_第10页

Cross-sectional risk models using quantitative fecal hemoglobin in colorectal cancer screening: a systematic review. 在结直肠癌癌症筛查中使用定量粪便血红蛋白的跨节风险模型：一项系统综述。

IF 5.1 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2023-07-01 Epub Date: 2023-12-15 DOI: 10.1080/14737159.2023.2279607

Tim Kortlever, Willemijn de Klaver, Manon van der Vlugt, Gerrit Meijer, Evelien Dekker, Patrick Bossuyt

{"title":"Cross-sectional risk models using quantitative fecal hemoglobin in colorectal cancer screening: a systematic review.","authors":"Tim Kortlever, Willemijn de Klaver, Manon van der Vlugt, Gerrit Meijer, Evelien Dekker, Patrick Bossuyt","doi":"10.1080/14737159.2023.2279607","DOIUrl":"10.1080/14737159.2023.2279607","url":null,"abstract":"Introduction: Fecal Immunochemical Testing (FIT) is a central tool in colorectal cancer (CRC) screening. To improve the selection of individuals for colonoscopy, risk models combining FIT with additional CRC risk factors have been developed. This systematic review aims to provide an overview of the current noninvasive FIT-based risk models for CRC screening to facilitate future implementation.Methods: We performed a systematic literature search for risk models that combined quantitative fecal hemoglobin with clinical data or noninvasive biomarkers and that were intended for CRC screening. Risk of bias was assessed using the PROBAST tool.Results: Twenty risk models reported across 29 publications were included. The overall risk of bias was high. In studies that compared risk models to FIT, 11/12 (92%) risk models had a significantly higher c-statistic than FIT only. 16/20 risk models (80%) had not been externally validated and only one model has been implemented so far.Conclusion: FIT-based risk models have the potential to improve the yield of CRC screening. Unfortunately, all included publications had a high risk of bias and most risk models have not yet been externally validated. The prospect of improved CRC screening with risk models should encourage more rigorous evaluation in existing screening programs.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71479816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostics in skeletal muscle channelopathies. 骨骼肌通道病的诊断。

IF 5.1 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2023-07-01 Epub Date: 2023-12-15 DOI: 10.1080/14737159.2023.2288258

Alex Vicino, Raffaella Brugnoni, Lorenzo Maggi

{"title":"Diagnostics in skeletal muscle channelopathies.","authors":"Alex Vicino, Raffaella Brugnoni, Lorenzo Maggi","doi":"10.1080/14737159.2023.2288258","DOIUrl":"10.1080/14737159.2023.2288258","url":null,"abstract":"Introduction: Skeletal muscle channelopathies (SMCs) are a heterogenous group of disorders, caused by mutations in skeletal ion channels leading to abnormal muscle excitability, resulting in either delayed muscle relaxation (myotonia) which characterizes non-dystrophic myotonias (NDMs), or membrane transient inactivation, causing episodic weakness, typical of periodic paralyses (PPs).Areas covered: SMCs include myotonia congenita, paramyotonia congenita, and sodium-channel myotonia among NDMs, and hyper-normokalemic, hypokalemic, or late-onset periodic paralyses among PPs. When suspecting an SMC, a structured diagnostic approach is required. Detailed personal and family history and clinical examination are essential, while neurophysiological tests should confirm myotonia and rule out alternative diagnosis. Moreover, specific electrodiagnostic studies are important to further define the phenotype of de novo cases and drive molecular analyses together with clinical data. Definite diagnosis is achieved through genetic testing, either with Sanger sequencing or multigene next-generation sequencing panel. In still unsolved patients, more advanced techniques, as exome-variant sequencing or whole-genome sequencing, may be considered in expert centers.Expert opinion: The diagnostic approach to SMC is still mainly based on clinical data; moreover, definite diagnosis is sometimes complicated by the difficulty to establish a proper genotype-phenotype correlation. Lastly, further studies are needed to allow the genetic characterization of unsolved patients.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138440479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Next generation immuno-oncology biomarkers in gastrointestinal cancer: what does the future hold? 胃肠道癌症的下一代免疫生态学生物标志物：未来如何？

IF 5.1 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2023-07-01 Epub Date: 2023-08-31 DOI: 10.1080/14737159.2023.2252739

Hassan Abushukair, Obada Ababneh, Ayah Al-Bzour, Ibrahim Halil Sahin, Anwaar Saeed

{"title":"Next generation immuno-oncology biomarkers in gastrointestinal cancer: what does the future hold?","authors":"Hassan Abushukair, Obada Ababneh, Ayah Al-Bzour, Ibrahim Halil Sahin, Anwaar Saeed","doi":"10.1080/14737159.2023.2252739","DOIUrl":"10.1080/14737159.2023.2252739","url":null,"abstract":"Introduction: Gastrointestinal (GI) cancers pose a significant health burden worldwide, necessitating advancements in diagnostic and treatment approaches. One promising avenue is the utilization of next-generation biomarkers, which hold the potential to revolutionize GI cancer management.Areas covered: This review explores the latest breakthroughs and expert opinions surrounding the application of next-generation immunotherapy biomarkers. It encompasses various aspects of the currently utilized biomarkers of immunotherapy in the context of GI cancers focusing on microsatellite stable cancers. It explores the promising research on the next generation of biomarkers addressing the challenges associated with integrating them into clinical practice and the need for standardized protocols and regulatory guidelines.Expert opinion: Immune profiling, multiplex immunohistochemistry, analysis of immune cell subsets, and novel genomic and epigenomic markers integrated with machine-learning approaches offer new avenues for identifying robust biomarkers. Liquid biopsy-based approaches, such as circulating tumor DNA (ctDNA) and exosome-based analyses, hold promise for real-time monitoring and early detection of treatment response.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10482278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Site-specific protein biomarkers in gastric cancer: a comprehensive review of novel biomarkers and clinical applications. 癌症位点特异性蛋白质生物标志物：新生物标志物及其临床应用综述。

IF 5.1 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2023-07-01 Epub Date: 2023-07-04 DOI: 10.1080/14737159.2023.2232298

Takahiro Shinozuka, Mitsuro Kanda, Yasuhiro Kodera

{"title":"Site-specific protein biomarkers in gastric cancer: a comprehensive review of novel biomarkers and clinical applications.","authors":"Takahiro Shinozuka, Mitsuro Kanda, Yasuhiro Kodera","doi":"10.1080/14737159.2023.2232298","DOIUrl":"10.1080/14737159.2023.2232298","url":null,"abstract":"Introduction: Gastric cancer (GC) is the fifth most common cancer and the fourth leading cause of cancer-related death worldwide, thus representing a significant global health burden. Early detection and monitoring of GC are essential to improve patient outcomes. While traditional cancer biomarkers such as carcinoembryonic antigen, carbohydrate antigen (CA) 19-9, and CA 72-4 are widely used, their limited sensitivity and specificity necessitate the exploration of alternative biomarkers.Areas covered: This review comprehensively analyzes the landscape of GC protein biomarkers identified from 2019 to 2022, with a focus on tissue, blood, urine, saliva, gastric juice, ascites, and exhaled breath as sample sources. We address the potential clinical applications of these biomarkers in early diagnosis, monitoring recurrence, and predicting survival and therapeutic response of GC patients.Expert opinion: The discovery of novel protein biomarkers holds great promise for improving the clinical management of GC. However, further validation in large, diverse cohorts is needed to establish the clinical utility of these biomarkers. Integrating these biomarkers with existing diagnostic and monitoring approaches will likely lead to improved personalized treatment plans and patient outcomes.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9853177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomarkers to guide immunomodulatory treatment: where do we stand? 指导免疫调节治疗的生物标志物：我们的立场是什么？

IF 5.1 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2023-07-01 Epub Date: 2023-09-10 DOI: 10.1080/14737159.2023.2258063

Evdoxia Kyriazopoulou, Evangelos J Giamarellos-Bourboulis, Karolina Akinosoglou

{"title":"Biomarkers to guide immunomodulatory treatment: where do we stand?","authors":"Evdoxia Kyriazopoulou, Evangelos J Giamarellos-Bourboulis, Karolina Akinosoglou","doi":"10.1080/14737159.2023.2258063","DOIUrl":"10.1080/14737159.2023.2258063","url":null,"abstract":"Introduction: This review summarizes current progress in the development of biomarkers to guide immunotherapy in oncology, rheumatology, and critical illness.Areas covered: An extensive literature search was performed about biomarkers classifying patients' immune responses to guide immunotherapy in oncology, rheumatology, and critical illness. Surface markers, such as programmed death-ligand 1 (PD-L1), genetic biomarkers, such as tumor mutation load, and circulating tumor DNA are biomarkers associated with the effectiveness of immunotherapy in oncology. Genomics, metabolomics, and proteomics play a crucial role in selecting the most suitable therapeutic options for rheumatologic patients. Phenotypes and endotypes are a promising approach to detect critically ill patients with hyper- or hypo-inflammation. Sepsis trials using biomarkers such as ferritin, lymphopenia, HLA-DR expression on monocytes and PD-L1 to guide immunotherapy have been already conducted or are currently ongoing. Immunotherapy in COVID-19 pneumonia, guided by C-reactive protein and soluble urokinase plasminogen activator receptor (suPAR) has improved patient outcomes globally. More research is needed into immunotherapy in other critical conditions.Expert opinion: Targeted immunotherapy has improved outcomes in oncology and rheumatology, paving the way for precision medicine in the critically ill. Transcriptomics will play a crucial role in detecting the most suitable candidates for immunomodulation.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10257127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical application of circulating tumor DNA in metastatic cancers. 循环肿瘤DNA在转移癌中的临床应用。

IF 5.1 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2023-07-01 Epub Date: 2023-12-15 DOI: 10.1080/14737159.2023.2268008

Negin Raei, Reza Safaralizadeh, Saeid Latifi-Navid

{"title":"Clinical application of circulating tumor DNA in metastatic cancers.","authors":"Negin Raei, Reza Safaralizadeh, Saeid Latifi-Navid","doi":"10.1080/14737159.2023.2268008","DOIUrl":"10.1080/14737159.2023.2268008","url":null,"abstract":"Introduction: Advances in genomics have facilitated the application of cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) in phase II and phase III clinical trials. The various mutations of cfDNA/ctDNA have been correlated with clinical features. Advances in next-generation sequencing (NGS) and digital droplet PCR have paved the way for identifying cfDNA/ctDNA mutations.Areas covered: Herein, the biology of ctDNA and its function in clinical application in metastasis, which may lead to improved clinical management of metastatic cancer patients, are comprehensively reviewed.Expert opinion: Metastatic cancer ctDNA shows the greatest frequency of mutations in TP53, HER-2, KRAS, and EGFR genes (alteration frequency of > 50%). Therefore, identifying key mutations frequently present in metastatic cancers can help identify patients with pre-malignant tumors before cancer progression. Studying ctDNA can help determine the prognosis and select appropriate treatments for affected patients. Nevertheless, the obstacles to detecting and analyzing ctDNA should be addressed before translation into routine practice. Also, more clinical trials should be conducted to study the significance of ctDNA in commonly diagnosed malignancies. Given the recent advances in personalized anti-neoplastic treatments, further studies are needed to detect a panel of ctDNA and patient-specific ctDNA for various cancers.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41144420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retrospective analysis of persistent HyperCKemia with or without muscle weakness in a case series from Greece highlights vast DMD variant heterogeneity. 在希腊的一系列病例中，对伴有或不伴有肌无力的持续性高肌酸激酶血症的回顾性分析突出了巨大的异质性DMD基因变异。

IF 5.1 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2023-07-01 Epub Date: 2023-10-24 DOI: 10.1080/14737159.2023.2264181

Kyriaki Kekou, Maria Svingou, Nikos Vogiatzakis, Evangelia Nitsa, Danai Veltra, Nikolaos M Marinakis, Faidon-Nikolaos Tilemis, Maria Tzetis, Anastasios Mitrakos, Charalambia Tsaroucha, Nicoletta Selenti, Giorgos-Konstantinos Papadimas, Constantinos Papadopoulos, Joanne Traeger-Synodinos, Hanns Lochmuller, Christalena Sofocleous

{"title":"Retrospective analysis of persistent HyperCKemia with or without muscle weakness in a case series from Greece highlights vast DMD variant heterogeneity.","authors":"Kyriaki Kekou, Maria Svingou, Nikos Vogiatzakis, Evangelia Nitsa, Danai Veltra, Nikolaos M Marinakis, Faidon-Nikolaos Tilemis, Maria Tzetis, Anastasios Mitrakos, Charalambia Tsaroucha, Nicoletta Selenti, Giorgos-Konstantinos Papadimas, Constantinos Papadopoulos, Joanne Traeger-Synodinos, Hanns Lochmuller, Christalena Sofocleous","doi":"10.1080/14737159.2023.2264181","DOIUrl":"10.1080/14737159.2023.2264181","url":null,"abstract":"Background: Persistent hyperCKemia results from muscle dysfunction often attributed to genetic alterations of muscle-related genes, such as the dystrophin gene (DMD). Retrospective assessment of findings from DMD analysis, in association with persistent HyperCKemia, was conducted.Patients and methods: Evaluation of medical records from 1354 unrelated cases referred during the period 1996-2021. Assessment of data concerning the detection of DMD gene rearrangements and nucleotide variants.Results: A total of 730 individuals (657 cases, 569 of Greek and 88 of Albanian origins) were identified, allowing an overall estimation of dystrophinopathy incidence at ~1:3800 live male births. The heterogeneous spectrum of 275 distinct DMD alterations comprised exon(s) deletions/duplications, nucleotide variants, and rare events, such as chromosome translocation {t(X;20)}, contiguous gene deletions, and a fused gene involving the DMD and the DOCK8 genes. Ethnic-specific findings include a common founder variant in exon 36 ('Hellenic' variant).Conclusions: Some 50% of hyperCKemia cases were characterized as dystrophinopathies, highlighting that DMD variants may be considered the most common cause of hyperCKemia in Greece. Delineation of the broad genetic and clinical heterogeneity is fundamental for actionable public health decisions and theragnosis, as well as the establishment of guidelines addressing ethical considerations, especially related to the mild asymptomatic patient subgroup.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41164455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

LncRNA NR2F1-AS1 as a potential biomarker for prognosis in cancer patients: meta and bioinformatics analysis. LncRNA NR2F1-AS1作为癌症患者预后的潜在生物标志物：元分析和生物信息学分析。

IF 5.1 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2023-07-01 Epub Date: 2023-12-15 DOI: 10.1080/14737159.2023.2277521

Lu Tang, Qing-Mei Liu, Shuang Zhang, Jun Zhou

{"title":"LncRNA NR2F1-AS1 as a potential biomarker for prognosis in cancer patients: meta and bioinformatics analysis.","authors":"Lu Tang, Qing-Mei Liu, Shuang Zhang, Jun Zhou","doi":"10.1080/14737159.2023.2277521","DOIUrl":"10.1080/14737159.2023.2277521","url":null,"abstract":"Background: Previous studies have shown that the differential expression of lncRNA NR2F1-AS1 is closely related to the prognosis of cancer, but the conclusion is still controversial. Therefore, we conducted a meta-analysis and bioinformatics analysis to explore the correlation between LncRNA NR2F1-AS1 and cancer prognosis.Methods: From the beginning to January 25, 2023, we searched for correlational studies on PubMed, Embase, the Cochrane Library, and Web of Science. We used pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) to determine the importance of LncRNA NR2F1-AS1 for survival and clinicopathological features of human cancers.Results: The meta-analysis of 637 patients in the 11 included articles showed that upregulation of LncRNA NR2F1-AS1 was associated with shorter overall survival (HR = 1.46,95%Cl 1.06-2.01, p = 0.02) in cancer patients. In addition, overexpression of LncRNA NR2F1-AS1 predicted TNM tumor stage (OR = 3.37, 95%Cl 2.07-5.48, p < 0.00001), and Distant metastasis (OR = 0.18, 95%Cl 0.06-0.48, p = 0.0007). However, the difference in age (OR = 1.10,95%Cl 0.71-1.71, p = 0.67), gender (OR = 1.26,95%Cl 0.79-2.00, p = 0.34), Lymph node metastasis (OR = 1.44,95%Cl 0.27-7.80, p = 0.67) or larger tumor size (OR = 1.56,95%Cl 0.48-5.08, p = 0.46) was not statistically significant.Conclusion: Upregulation of LncRNA NR2F1-AS1 was associated with poor prognosis and advanced clinicopathologic features of tumor patients.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71411261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of a novel epigenetic marker for typical and mosaic presentations of Fragile X syndrome. 脆性X综合征典型和镶嵌表现的新表观遗传标记的鉴定。

IF 5.1 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2023-07-01 Epub Date: 2023-12-15 DOI: 10.1080/14737159.2023.2284782

Camilla Pereira da Silva, Diego Camuzi, Adriana Helena de Oliveira Reis, Andressa Pereira Gonçalves, Jussara Mendonça Dos Santos, Filipe Brum Machado, Enrique Medina-Acosta, Sheila Coelho Soares-Lima, Cíntia Barros Santos-Rebouças

{"title":"Identification of a novel epigenetic marker for typical and mosaic presentations of Fragile X syndrome.","authors":"Camilla Pereira da Silva, Diego Camuzi, Adriana Helena de Oliveira Reis, Andressa Pereira Gonçalves, Jussara Mendonça Dos Santos, Filipe Brum Machado, Enrique Medina-Acosta, Sheila Coelho Soares-Lima, Cíntia Barros Santos-Rebouças","doi":"10.1080/14737159.2023.2284782","DOIUrl":"10.1080/14737159.2023.2284782","url":null,"abstract":"Background: Fragile X syndrome (FXS) is primarily due to CGG repeat expansions in the FMR1 gene. FMR1 alleles are classified as normal (N), intermediate (I), premutation (PM), and full mutation (FM). FXS patients often carry an FM, but size mosaicism can occur. Additionally, loss of methylation boundary upstream of repeats results in de novo methylation spreading to FMR1 promoter in FXS patients.Research design and methods: This pilot study investigated the methylation boundary and adjacent regions in 66 males with typical and atypical FXS aged 1 to 30 years (10.86 ± 6.48 years). AmplideX FMR1 mPCR kit was used to discriminate allele profiles and methylation levels. CpG sites were assessed by pyrosequencing.Results: 40 out of 66 FXS patients (60.6%) showed an exclusive FM (n = 40), whereas the remaining (n = 26) exhibited size mosaicism [10 PM_FM (15.15%); 10 N_FM (15.15%); 2 N_PM_FM (3%)]. Four patients (6.1%) had deletions near repeats. Noteworthy, a CpG within FMR1 intron 2 displayed hypomethylation in FXS patients and hypermethylation in controls, demonstrating remarkable specificity, sensitivity, and accuracy when a methylation threshold of 69.5% was applied.Conclusions: Since intragenic methylation is pivotal in gene regulation, the intronic CpG might be a novel epigenetic biomarker for FXS diagnosis.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136396963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synovial biopsies for molecular definition of rheumatoid arthritis and treatment response phenotyping: where can we improve? 滑膜活检对类风湿关节炎的分子定义和治疗反应表型:我们可以在哪里改进?

IF 5.1 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2023-07-01 Epub Date: 2023-12-15 DOI: 10.1080/14737159.2023.2284774

Francesco Salvatore Iaquinta, Felice Rivellese, Costantino Pitzalis

{"title":"Synovial biopsies for molecular definition of rheumatoid arthritis and treatment response phenotyping: where can we improve?","authors":"Francesco Salvatore Iaquinta, Felice Rivellese, Costantino Pitzalis","doi":"10.1080/14737159.2023.2284774","DOIUrl":"10.1080/14737159.2023.2284774","url":null,"abstract":"Introduction: The extensive knowledge gained in the cellular and molecular mechanisms underlying Rheumatoid Arthritis (RA) pathogenesis has led to therapeutic advances. However, up to 10-20% of patients fail to respond to multiple therapeutic agents being classified as multi-drugresistant. A key challenge moving forward will be the implementation of synovial biopsies in clinical practice to facilitate the shift from the current trial-and-error strategy toward new forms of clinical trials. Biomarker-driven trials have the potential to improve drug selection and patient stratification, reduce economic costs and unnecessary drug-related toxicity.Areas covered: This special report explores the clinical and research applications of synovial biopsy, the advancement in the molecular pathobiology of RA to better understand disease pathogenesis and treatment response, and the way forward for the paradigm shift needed.Expert opinion: In the current era of highly targeted biologic drugs which have dramatically transformed the outlook of RA patients, the use of synovial biopsy represents a valuable practical tool to dissect disease pathogenesis and, consequently, treatment response. In the near future, it is hoped that technological advances will allow for speeding up synovial molecular analysis and that the design of new biomarker-driven trials will enable the allocation of patients to more effective treatment.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136396964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0